Postherpetic Neuralgia Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Ono Pharmaceutical Co. Ltd, Undaunted Bio, INC, Shanghai SIMR Biotechnology Co., Ltd.

Postherpetic Neuralgia Pipeline constitutes 3+ key companies continuously working towards developing 3+ Postherpetic Neuralgia treatment therapies, analyzes DelveInsight.

Postherpetic Neuralgia Overview:

Postherpetic neuralgia (PHN) is a frequent and painful complication that can follow a shingles outbreak, caused by reactivation of the varicella-zoster virus. It is marked by ongoing, burning or stabbing pain along the area of the skin where the shingles rash appeared, typically lasting for three months or more after the rash resolves. Older adults and those with weakened immune systems are at higher risk.

Symptoms include sharp, burning, or aching pain, often accompanied by increased sensitivity to touch, itching, or numbness. In severe cases, PHN can disrupt sleep, daily activities, and emotional well-being, potentially leading to anxiety or depression.

Treatment is often complex and may involve a combination of medications like anticonvulsants, antidepressants, topical creams, and nerve blocks. However, pain relief is not always complete. Vaccination against shingles is the most effective preventive measure, significantly lowering the risk of both shingles and PHN. Once PHN develops, early and ongoing management is crucial to reduce symptoms and maintain quality of life.

Request for a detailed insights report on Postherpetic Neuralgia pipeline insights https://www.delveinsight.com/report-store/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Postherpetic Neuralgia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Postherpetic Neuralgia Therapeutics Market.

Key Takeaways from the Postherpetic Neuralgia Pipeline Report

DelveInsight's Postherpetic Neuralgia pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Postherpetic Neuralgia treatment.
On June 17, 2025, the FDA approved a prefilled syringe presentation of Shingrix, the recombinant zoster vaccine used to prevent shingles and associated PHN. This new format eliminates the need for reconstitution, simplifying administration for healthcare providers and potentially improving vaccine uptake and convenience.
Key Postherpetic Neuralgia companies such as Ono Pharmaceutical Co. Ltd, Undaunted Bio, INC, Shanghai SIMR Biotechnology Co., Ltd., and others are evaluating new drugs for Postherpetic Neuralgia to improve the treatment landscape.
Promising Postherpetic Neuralgia pipeline therapies in various stages of development include ONO-1110, UDB412, and others.

Postherpetic Neuralgia Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Postherpetic Neuralgia Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postherpetic Neuralgia treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postherpetic Neuralgia market.

Download our free sample page report on Postherpetic Neuralgia pipeline insights https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Postherpetic Neuralgia Emerging Drugs

ONO-1110 - Ono Pharmaceutical Co. Ltd

ONO-1110 is an experimental treatment in development for Postherpetic Neuralgia (PHN) by Ono Pharmaceutical. Currently in Phase II clinical trials in Japan, the drug is being assessed for its ability to relieve pain and offer additional pharmacological advantages with a better safety profile than standard therapies.

UDB412 - Undaunted Bio, Inc.

UDB412 is a repurposed medication being reformulated by Undaunted Bio into an Oral Thin Film (OTF) to treat pain in patients with Trigeminal Neuralgia. Developed under the FDA's 505(b)(2) regulatory pathway, this new OTF version allows the drug to dissolve on the tongue without water, making it easier for patients to take even during an attack. This delivery method could significantly improve pain management and patient convenience. UDB412 is currently in the discovery phase for its potential use in treating Postherpetic Neuralgia.

Postherpetic Neuralgia Companies

There are over three major companies currently working on developing treatments for Postherpetic Neuralgia. Among them, Ono Pharmaceutical Co. Ltd. has a drug candidate that is in the most advanced stage of development-Phase II.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Postherpetic Neuralgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Postherpetic Neuralgia Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Postherpetic Neuralgia Therapies and Key Companies: Postherpetic Neuralgia Clinical Trials and advancements https://www.delveinsight.com/report-store/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Postherpetic Neuralgia Pipeline Therapeutic Assessment
• Postherpetic Neuralgia Assessment by Product Type
• Postherpetic Neuralgia By Stage
• Postherpetic Neuralgia Assessment by Route of Administration
• Postherpetic Neuralgia Assessment by Molecule Type

Download Postherpetic Neuralgia Sample report to know in detail about the Postherpetic Neuralgia treatment market @ Postherpetic Neuralgia Therapeutic Assessment https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Postherpetic Neuralgia Current Treatment Patterns
4. Postherpetic Neuralgia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Postherpetic Neuralgia Late-Stage Products (Phase-III)
7. Postherpetic Neuralgia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Postherpetic Neuralgia Discontinued Products
13. Postherpetic Neuralgia Product Profiles
14. Postherpetic Neuralgia Key Companies
15. Postherpetic Neuralgia Key Products
16. Dormant and Discontinued Products
17. Postherpetic Neuralgia Unmet Needs
18. Postherpetic Neuralgia Future Perspectives
19. Postherpetic Neuralgia Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Postherpetic Neuralgia Pipeline Reports Offerings https://www.delveinsight.com/report-store/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.